Novartis

Tatjana Dreyer wird Head Communications & Patient Advocacy bei Novartis Deutschland

Soll ich mein eigenes, erkranktes Kind an einer klinischen Studie teilnehmen lassen? Viele Eltern würden diese Frage wohl instinktiv verneinen. Doch was ist, wenn es kein wirksames und sicheres ...
Novartis

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer pati…

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...
Novartis

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...
Novartis

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...
Novartis

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Novartis’ commitment to kidney diseases Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, ...
Novartis

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast-to-coast RLT manufacturing network – the largest in the US ...
Novartis

New long term social impact and sustainability targets

Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support ...
Novartis

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for ...
Novartis

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...
Novartis

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...
Novartis

Supercharging R&D: How AI helps us to bring medicines to patients faster

Max leads AI innovation in pharmaceutical development at Novartis. His story reflects how cutting-edge technology is combined with human expertise for meaningful impact. “I didn’t set out to work in ...